Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina said Thursday it has won in the Federal Trade Commission's case challenging its $7.1 billion acquisition of cancer detection company GRAIL.

Illumina wins FTC GRAIL case in $7.1 billion deal

An administrative law judge rejects the Federal Trade Commission's challenge of Illumina's acquisition last year of Grail.

FTC Challenge of Illumina's Acquisition of Grail Rejected by Judge

The case was seen as a test of a more aggressive policy by the agency.

Illumina defeats F.T.C. in major antitrust case.

Illumina Inc said on Thursday an administrative judge has ruled that its acquisition of cancer detection test maker Grail Inc will not hurt competition, allowing the deal to move forward.

Illumina says judge rules Grail deal will not hurt competition

WASHINGTON , Sept. 1, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today received a favorable decision from the Administrative Law Judge (ALJ) presiding over the Federal Trade Commission's (FTC) challenge of the GRAIL acquisition.

Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal

A judge has ruled in favor of Illumina Inc in its acquisition of Grail Inc dealing a blow to the U.S. Federal Trade Commission's efforts to unwind the multi-billion-dollar deal, the Wall Street Journal reported on Thursday, citing people familiar with the matter.

Illumina wins case against U.S. FTC on Grail purchase - WSJ

Illumina (ILMN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here is What to Know Beyond Why Illumina, Inc. (ILMN) is a Trending Stock

Investment in new Shanghai-based facility will allow the company to better serve its customers and meet growing demand SAN DIEGO , Aug. 30, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of its first manufacturing site in China. The new Shanghai-based facility enables localized production for Illumina's gene sequencing instruments and consumables and reflects the growing demand in the Chinese market for Illumina's systems and products.

Illumina Deepens Commitment to Customers in China with New Manufacturing Site

Global conference to focus on advancing the life-saving impacts of genomic health care SAN DIEGO , Aug. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Tennis Hall of Fame member Chris Evert as a special guest at its inaugural Illumina Genomics Forum (IGF) on October 1. Evert, who was diagnosed with stage 1C ovarian cancer earlier this year, will participate in a fireside chat discussing how genomics can improve early cancer detection, lead to more proactive, effective treatment of cancer, and help save lives.

Illumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight

Session will focus on disrupting the status quo by empowering consumers to make more proactive, informed health care decisions SAN DIEGO , Aug. 22, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Anne Wojcicki, co-founder and CEO of personal genomics company 23andMe, at its inaugural Illumina Genomics Forum (IGF) on October 1. In a spotlight session titled "Disruption Ahead," Wojcicki will speak with biotechnology journalist Luke Timmerman about putting the consumer at the center of health care, drawing from her personal experience disrupting the health care status quo, and improving patient lives through genomics innovation.

Illumina Genomics Forum to Feature 23andMe Co-founder and CEO Anne Wojcicki

There's an acquisition-driven crisis brewing, not to mention some headwinds.

2 Red Flags and 1 Green Flag For Illumina Stock

Zacks.com users have recently been watching Illumina (ILMN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Trending Stock Illumina, Inc. (ILMN) a Buy Now?

Agilent Technologies

Agilent Technologies proved its worth in FQ3 and was able to raise guidance as well, sending its shares higher as it continues to outperform Illumina.

Agilent Technologies Proves Its Worth VS Illumina

New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods SAN DIEGO , Aug. 16, 2022 /PRNewswire/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a 40 million Australian dollar (US $27.8 million) partnership that will leverage the power of genomics to accelerate scientific understanding of marine systems and help marine conservationists make informed decisions. The three-year partnership demonstrates a shared commitment to conserving marine biodiversity and understanding the changing marine ecosystems on which people and national economies depend.

Minderoo Foundation and Illumina Commit $40M AUD to Apply Advanced Genomics to Marine Conservation

Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.

Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View

Session will showcase the rapidly growing use and groundbreaking impact of clinical genomics in oncology SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Dr. Karen Knudsen, CEO of the American Cancer Society, at its inaugural Illumina Genomics Forum (IGF) on October 1. Dr. Knudsen will participate in an on-stage conversation with Dr. Phil Febbo, Illumina's Chief Medical Officer, about the landscape of cancer treatment and research, including what is currently being done to support the prevention, detection, and treatment of cancer.

Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics

Illumina (NASDAQ: ILMN ) stock is down nearly 10% today after a tumultuous second quarter earnings call. The California-based gene-sequencing company failed to meet Wall Street consensus revenue and earnings estimates.

Why Is Illumina (ILMN) Stock Plunging 10% Today?

The shares of Illumina Inc (NASDAQ:ILMN) are down 9.6% at $205.71 at last check, and earlier dipped as low as $198, after the company announced worse-than-expected second-quarter results and a disappointing full-year revenue forecast.

Illumina Stock Slips After Disappointing Results

Illumina stock crashed Friday after the DNA sequencer broadly lagged Wall Street's quarterly forecasts and slashed its outlook for the year. The post Illumina, DNA Sequencer, Crashes As Covid, China Hammer Quarterly Results appeared first on Investor's Business Daily.

Illumina, DNA Sequencer, Crashes As Covid, China Hammer Quarterly Results

Illumina Inc (NASDAQ:ILMN) shares are due to plummet on Friday after the gene sequencing company swung to a loss in the second quarter as revenue fell short of expectations and it cut its full-year outlook. Revenue grew 3% year over year to US$1.16bn, up 5% on a constant-currency basis, but lower than the consensus estimate of US$1.22bn.

Illumina swings to loss and cuts growth guidance

Illumina, Inc. (NASDAQ:ILMN ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Salli Schwartz - Vice President, Investor Relations Francis deSouza - President & Chief Executive Officer Joydeep Goswami - Chief Strategy & Corporate Development Officer, Interim Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Dan Brennan - Cowen Dan Arias - Stifel David Westenberg - Piper Sandler Julia Qin - JPMorgan Tejas Savant - Morgan Stanley Puneet Souda - SVB Securities Kyle Mikson - Canaccord Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Jack Meehan - Nephron Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2022 Illumina Earnings Conference Call. At this time, all participants are in listen-only mode.

Illumina, Inc. (ILMN) CEO Francis deSouza on Q2 2022 Results - Earnings Call Transcript

Illumina (ILMN) delivered earnings and revenue surprises of -9.52% and 4.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q2 Earnings and Revenues Lag Estimates

Illumina Inc. shares sank more than 22% after hours Thursday after the gene-sequencing company swung to a loss in the second quarter, fell short of revenue expectations and revised its full-year outlook downward.

Illumina stock tanks as gene-sequencing company misses expectations and issues bleak outlook

Revenue of $1.16 billion for Q2 2022, up 3% from Q2 2021, and up 5% on a constant currency basis GAAP diluted loss per share of $(3.40) for Q2 2022, compared to GAAP diluted earnings per share of $1.26 for Q2 2021; GAAP diluted loss per share for Q2 2022 includes $609 million in legal contingencies Non-GAAP diluted earnings per share of $0.57 for Q2 2022, compared to non-GAAP diluted earnings per share of $1.87 for Q2 2021 Expect full year revenue for fiscal year 2022 to grow 4% to 5% from fiscal year 2021, primarily reflecting the ongoing negative impact of foreign exchange rates, customer lab expansion delays, and macroeconomic-driven conservatism around immediate capital and inventory commitments, including in Greater China Expect GAAP diluted loss per share of $(2.93) to $(2.78) for fiscal year 2022 Expect non-GAAP diluted earnings per share of $2.75 to $2.90 for fiscal year 2022 SAN DIEGO , Aug. 11, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the second quarter of fiscal year 2022, which include consolidated financial results for GRAIL. "Our second quarter results did not meet our expectations as challenges in a complex macroeconomic environment more than offset the growth we continue to see in sequencing runs on our platforms," said Francis deSouza, Chief Executive Officer.

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022

Just in its latest quarter, ILMN registered a solid 23% bottom-line beat.

News for Illumina Stock (ILMN)